HealthJune 13, 2026

New TALVEY® and Daratumumab Combination Shows Promise for Multiple Myeloma Treatment

Johnson & Johnson's Phase 3 MonumenTAL-3 study presents promising data for TALVEY® in combination with daratumumab. The findings could transform treatment strategies for relapsed or refractory multiple myeloma patients.

Mateo Dela CruzRead

HealthJune 6, 2026

Cullinan Therapeutics Unveils Initial Clinical Data for CLN-978 at EULAR 2026

Cullinan Therapeutics presented promising initial data for CLN-978, highlighting its potential as a treatment for systemic lupus erythematosus and rheumatoid arthritis at the EULAR 2026 Congress. The findings suggest significant clinical benefits, including remissions and favorable safety profiles.

Mateo Dela CruzRead